Skip to main content

Table 2 Response to nab-paclitaxel in the intent-to-treat population

From: A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer

Response Number of patients %
 Complete response 0 0
 Partial response 6 19.3
 Stable disease 17 54.8
 Progressive disease 8 25.9
Response Rate 19.3% (95% CI, 9.1%–36.2%) (90% CI, 10.3%–33.2%)
Disease control rate 25 74.1
  1. CI confidence interval